In a clinical context, where the tumor lesion is infiltrated with IgG4+ B cells expressing high-affinity tumor antigen-specific IgG4s [41••], a valid tool for active immunotherapy could be the implementation of immunization approaches that support tumor-localized isotype switching from IgG4 to more potent IgE antibodies, via the indirect route. Here, IGHE is linked to neoplasm.